Takeda offers $2.2 billion settlement in Actos bladder cancer lawsuits, Bloomberg reports

Posted
by Jim Orr

Takeda Pharmaceutical has reportedly offered $2.2 billion to settle thousands of lawsuits filed against the drug company involving diabetes drug Actos and bladder cancer diagnosis in patients who used this medication. The settlement proposal, first reported by Bloomberg News, would be the first in the three-year Actos litigation history, which has involved more than 8,000 bladder cancer lawsuits in federal and state courts, and would be one of the largest pharmaceutical liability settlements ever reached in the U.S.

First sold in the U.S. in 1999, Actos is designed to help patients with type 2 diabetes by controlling blood glucose levels. In 2010, the Food and Drug Administration issued a warning about the drug following reports that linked Actos to an increased risk of bladder cancer for patients who took the drug for more than one year. Following these reports, health officials in France and Germany issued a recall notice for Actos; the FDA ordered Takeda to place a black box warning on the drug in the U.S. to warn patients about the increased bladder cancer risk.

Reports of Takeda’s Actos settlement offer come after a series of courtroom defeats in litigation involving the diabetes drug. Last year, a man who was diagnosed with bladder cancer after taking Actos obtained a $9 billion jury verdict in Louisiana. The verdict was later reduced by a judge to $36.8 million in damages. Juries in four other Actos lawsuits have also found Takeda liable for cases of bladder cancer that were linked to the drug.

Under the terms of the proposed settlement, Actos users who have been diagnosed with bladder cancer would be entitled to receive about $275,000 per case. Only patients who have already filed a lawsuit or who have hired an attorney in order to file litigation would be eligible to receive a settlement.

Legal experts say that Takeda’s Actos settlement offer is an effort by the company to stem the tide of litigation it currently faces from patients who were diagnosed with bladder cancer after taking the drug. The Japanese drugmaker is currently facing more than 3,500 Actos lawsuit in Louisiana federal court as well as an additional 4,500 lawsuits in state courts in California, Pennsylvania, Illinois, and West Virginia.

According to these lawsuits, Takeda executives ignored or downplayed the link between Actos and bladder cancer before the drug went on sale in the U.S. in 1999. The lawsuits also accuse the company of misleading U.S. regulators about the risks of Actos bladder cancer.

Heygood, Orr & Pearson and Actos Bladder Cancer Lawsuits

Despite Takeda’s Actos settlement offer, patients who have been diagnosed with bladder cancer after using the diabetes drug may still be eligible to file a lawsuit and receive compensation for their injuries. The first step in filing an Actos bladder cancer lawsuit is to speak with an experienced pharmaceutical litigation attorney who has the knowledge and experience to successfully handle your case.

Heygood, Orr & Pearson is pursuing Actos cases on behalf of clients who were diagnosed with bladder cancer after being prescribed the diabetes drug. Our law firm will be closely involved with the Actos multidistrict litigation (MDL) and other lawsuits filed against Actos involving bladder cancer.

The attorneys at Heygood, Orr & Pearson have extensive experience in handling lawsuits involving dangerous drugs or defective medical devices. Our lawyers have successfully collected more than $200 million for our clients in lawsuits relating to defective pharmaceutical products.

For a free legal consultation about your case to find out more about whether you may be eligible to file a lawsuit involving Actos and bladder cancer, contact the lawyers at Heygood, Orr & Pearson by calling toll-free at 1-877-446-9001, or by following this link to our free case evaluation form.